200 related articles for article (PubMed ID: 23292023)
1. [Regulatory authorities expect innovative drug delivery systems (DDS)].
Mori K
Yakugaku Zasshi; 2013; 133(1):73-80. PubMed ID: 23292023
[TBL] [Abstract][Full Text] [Related]
2. [Pharmaceuticals and Medical Devices Agency (PMDA)'s new action for Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy].
Masuyama K
Yakugaku Zasshi; 2013; 133(2):183-6. PubMed ID: 23370511
[TBL] [Abstract][Full Text] [Related]
3. [Impact of the last 15 years: from PMDEC to PMDA --looking back at the first stage of the PMDEC].
Morimoto K; Fujiwara Y; Kawahara A
Yakushigaku Zasshi; 2011; 46(1):38-50. PubMed ID: 22164689
[TBL] [Abstract][Full Text] [Related]
4. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.
Nagai S; Ozawa K
Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858
[TBL] [Abstract][Full Text] [Related]
5. [Molecular imaging-based early-phase and exploratory clinical research].
Watanabe Y
Yakugaku Zasshi; 2013; 133(2):187-95. PubMed ID: 23370512
[TBL] [Abstract][Full Text] [Related]
6. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.
Azuma K; Yamanaka S
Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486
[TBL] [Abstract][Full Text] [Related]
7. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
8. [Twenty-year History and Future Challenges in Transparency Enhancement of Review Process for Approval: Focus on Public Release of Review Reports regarding New Drugs and Medical Devices].
Morimoto K; Kawasaki S; Yoshida Y
Yakushigaku Zasshi; 2015; 50(1):64-77. PubMed ID: 26427100
[TBL] [Abstract][Full Text] [Related]
9. Regulatory/Scientific Supports for Micro-, Small-, and Medium-Sized Enterprises (SMEs) With Medicinal Products Provided by the PMDA and EMA.
Kondo H; Shibatsuji M; Yasuda N
Ther Innov Regul Sci; 2019 Mar; 53(2):193-198. PubMed ID: 29719977
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between the Review Time and Various PMDA Consultations in Recent New Drug Approval Cases in Japan.
Nishiyama K; Toyoshima S; Yamada H; Suzuki H; Nagai N
Ther Innov Regul Sci; 2018 Nov; 52(6):731-738. PubMed ID: 29714577
[TBL] [Abstract][Full Text] [Related]
11. Accelerating Regulatory Science Initiatives for the Development of Drugs for Alzheimer's Disease in Japan.
Moritoyo T
Clin Ther; 2015 Aug; 37(8):1622-6. PubMed ID: 26342202
[TBL] [Abstract][Full Text] [Related]
12. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
Maruyama H; Kondo T
Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
[TBL] [Abstract][Full Text] [Related]
13. [Current PMDA Activities for Use of Biomarkers in Drug Evaluation].
Ishiguro A
Yakugaku Zasshi; 2015; 135(5):681-4. PubMed ID: 25948301
[TBL] [Abstract][Full Text] [Related]
14. What to Know About Medicines With New Active Ingredients Approved in FY 2016 / 2016 in Japan and EU: A Brief Comparison of New Medicines Approved in Japan and the EU in 2016.
Kondo H; Saint-Raymond A; Yasuda N
Ther Innov Regul Sci; 2018 Mar; 52(2):214-219. PubMed ID: 29714521
[TBL] [Abstract][Full Text] [Related]
15. [Innovative approach for drug discovery by targeted therapy].
Kikuchi H; Kato K
Yakugaku Zasshi; 2013; 133(1):41-2. PubMed ID: 23292018
[No Abstract] [Full Text] [Related]
16. [Activity report on a programe of the Ministry of Health, Labour and Welfare (MHLW) "Initiative to facilitate development of innovative drugs, medical devices, and cellular and tissue-based products" in National Institute of Health Sciences].
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):1-2. PubMed ID: 25707193
[No Abstract] [Full Text] [Related]
17. [Overview of Analytical Techniques for Evaluation of Nano-DDS Formulations].
Sakai-Kato K
Yakugaku Zasshi; 2019; 139(2):255-260. PubMed ID: 30713236
[TBL] [Abstract][Full Text] [Related]
18. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
Okada K; Koike K; Sawa Y
Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of PMDA and EMA Consultations for Regulatory and Scientific Matters in Drugs and Regenerative Medicine Products.
Kondo H; Sugita T; Ida N; Fukushima H; Yasuda N
Ther Innov Regul Sci; 2017 May; 51(3):355-359. PubMed ID: 30231707
[TBL] [Abstract][Full Text] [Related]
20. Future development of artificial organs related with cutting edge emerging technology and their regulatory assessment: PMDA's perspective.
Handa N; Mochizuki S; Fujiwara Y; Shimokawa M; Wakao R; Arai H
J Artif Organs; 2020 Sep; 23(3):203-206. PubMed ID: 32112156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
